Skip to main content
Fig. 8 | Journal of Nanobiotechnology

Fig. 8

From: Targeted OUM1/PTPRZ1 silencing and synergetic CDT/enhanced chemical therapy toward uveal melanoma based on a dual-modal imaging-guided manganese metal–organic framework nanoparticles

Fig. 8

Pharmacokinetics and targeting effect and tumor suppression effects of intravenously injected NPs in vivo. a In vivo real-time bioluminescence imaging of UM tumor-bearing mice at different time points after administration of ICG-COP@MOF-PR. b ICG fluorescent intensities from ex vivo imaging of the major organs, and the tumors 24 h after injecting ICG-COP@MOF-PR. c T1-weighted MRI after intravenous injection with ICG-COP@MOF-PR at predesigned time points. d, e The tumor growth curves and bioluminescence imaging showed UM growth with different treatments in vivo. f Immunohistochemistry of Ki-67 of UM tumor samples with different treatments. Scale bar, 50 μm. g RNA in situ hybridization of lncRNA OUM1 (green) in tumor samples with different treatments. Scale bar, 20 μm. h RNA in situ hybridization of PTPRZ1 (green) in tumor samples with different treatments. Scale bar, 20 μm. i Bioluminescence imaging of M2b induced pulmonary metastasis models. j HE staining of metastasis nodes in the lung. Scale bar, 200 μm

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us